NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/21/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization449.38 mln
Float61.99 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
37.82
Transformational upside
Relative Strength
99
/ 100
Top performer
Debt / Equity
0.12
Very low leverage
ROE
-76.96
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Helus Pharma is a Toronto-based clinical-stage company working to develop new treatments for mental health conditions using compounds derived from psychedelics. Its most advanced programs include a modified form of psilocybin currently in Phase 3 trials for major depression, and a DMT-based compound in Phase 2 trials for generalized anxiety disorder. The company has additional candidates at earlier stages of development and works with Segal Trials to run a large multinational study evaluating its lead depression treatment.
